RhumbLine Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.9M | Sell |
|
|||||
|
2025
Q1 | $34.8M | Sell |
|
|||||
|
2024
Q4 | $43.7M | Sell |
|
|||||
|
2024
Q3 | $37.1M | Sell |
|
|||||
|
2024
Q2 | $44.6M | Buy |
|
|||||
|
2024
Q1 | $44.4M | Buy |
|
|||||
|
2023
Q4 | $42M | Sell |
|
|||||
|
2023
Q3 | $36.6M | Sell |
|
|||||
|
2023
Q2 | $31M | Buy |
|
|||||
|
2023
Q1 | $31M | Buy |
|
|||||
|
2022
Q4 | $35.8M | Buy |
|
|||||
|
2022
Q3 | $30.5M | Buy |
|
|||||
|
2022
Q2 | $27.1M | Buy |
|
|||||
|
2022
Q1 | $23.9M | Buy |
|
|||||
|
2021
Q4 | $21.7M | Buy |
|
|||||
|
2021
Q3 | $24.1M | Sell |
|
|||||
|
2021
Q2 | $24.5M | Sell |
|
|||||
|
2021
Q1 | $24.7M | Buy |
|
|||||
|
2020
Q4 | $10.9M | Sell |
|
|||||
|
2020
Q3 | $11.5M | Sell |
|
|||||
|
2020
Q2 | $15.6M | Buy |
|
|||||
|
2020
Q1 | $8.7M | Buy |
|
|||||
|
2019
Q4 | $10.8M | Buy |
|
|||||
|
2019
Q3 | $8.8M | Sell |
|
|||||
|
2019
Q2 | $8.29M | Buy |
|
|||||
|
2019
Q1 | $8.59M | Buy |
|
|||||
|
2018
Q4 | $6.95M | Sell |
|
|||||
|
2018
Q3 | $12.5M | Sell |
|
|||||
|
2018
Q2 | $10.2M | Buy |
|
|||||
|
2018
Q1 | $8.44M | Sell |
|
|||||
|
2017
Q4 | $8.13M | Sell |
|
|||||
|
2017
Q3 | $6.47M | Sell |
|
|||||
|
2017
Q2 | $4.97M | Sell |
|
|||||
|
2017
Q1 | $4.76M | Buy |
|
|||||
|
2016
Q4 | $4.15M | Buy |
|
|||||
|
2016
Q3 | $5.04M | Buy |
|
|||||
|
2016
Q2 | $4.23M | Sell |
|
|||||
|
2016
Q1 | $3.93M | Buy |
|
|||||
|
2015
Q4 | $5.51M | Buy |
|
|||||
|
2015
Q3 | $3.6M | Buy |
|
|||||
|
2015
Q2 | $4.17M | Sell |
|
|||||
|
2015
Q1 | $3.52M | Buy |
|
|||||
|
2014
Q4 | $1.53M | Sell |
|
|||||
|
2014
Q3 | $1.13M | Buy |
|
|||||
|
2014
Q2 | $1.05M | Buy |
|
|||||
|
2014
Q1 | $1.08M | Sell |
|
|||||
|
2013
Q4 | $654K | Sell |
|
|||||
|
2013
Q3 | $794K | Sell |
|
|||||
|
2013
Q2 | $947K | Buy |
|